Change in Management

6th July, 2026 Corporate Relationship Department The Manager - Listing M/s. BSE Limited M/s. National Stock Exchange of India Ltd Mumbai 400001 Bandra (E) Mumbai 400051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the above cited subject, we would like to inform you that in accordance with the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the below mentioned officials of the Company has been designated as follows w.e.f. 6th July, 2026: 1. Mr. Gnanadeva Chalapathy Gudipati has been designated as Senior Vice President - Analytical Research & Development; and 2. Mr. Madhava Rao Karicherla has been designated as Vice President – Formulation Research & Development, Pharma Division, Kothur Unit. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 and SEBI Master Circular No.HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 updated on January 30, 2026 are as under: Sl. No. PARTICULARS 1 Name Mr. Gnanadeva Chalapathy Gudipati Mr. Madhava Rao Karicherla 2 Reason for Designated as Senior Vice President - Designated as Vice President – Change in Senior Analytical Research & Development Formulation Research & Development, Management Pharma Division, Kothur Unit 3 Date of 6th July, 2026 & Terms of appointment are 6th July, 2026 & Terms of appointment Appointment & as per the Company’s Policy are as per the Company’s Policy Term of Appointment 4 Brief profile Mr. Gnanadeva Chalapathy Gudipati has Mr. Madhava Rao is an Innovative and rich experience in resolving complex Performance-driven Pharmaceutical technical problems in support of Professional with 20 plus years of rich corporate goals and objectives using and extensive experience in global scientific innovation, project Generic product development, ANDA management, learning, leadership & Filings, Project Life Cycle Management, ingenuity. Exposure to corporate Operations Management, Procurement operational / technical aspects, technical Strategy, Quality Management, due-diligence, Internal and External Budgeting, Team Management, and audits, technical write-ups & out- People Management across licensing. He has successfully developed Pharmaceutical Industry. He is also Complex injectable portfolio for the having expertise in Pre-formulation and organisation by developing complex formulation development of Oral Solid analytical methods and validating those Dosage forms (OSD’s) (Immediate Page 1 of 2 for the regulatory submissions as a part release and extended-release tablets, of product characterization through DR capsules), liquid orals and strong reverse engineering skills. parenteral dosage forms (dry powder injections, lyophilized preparations, He is associated with Natco Pharma liquid injections (aqueous and oily). He Limited since 15th September, 2017. Prior is also experienced in designing and to joining with NATCO Pharma Limited he implementation of first-to-file patent worked with Mylan Laboratories Limited non-infringing strategies for USA and European markets and exposure to He has done Executive Programme in Patents and Patent infringement Operations Management from Indian analysis to design patent non-infringing Institute of Management, Kozhikode and ANDAs for regulated markets. Master’s degree in Chemistry from Institute of Chemical Sciences, Indore, He is associated with Natco Pharma Madhya Pradesh. Limited since 15th November, 2024. Prior to joining with NATCO Pharma Limited Mr. Madhava Rao worked with Sandoz India Private Limited, Eugia Pharma Specialities Limited, Stabicon Life Sciences, Laurus Labs Limited, Abdi Ibrahim Pharmaceuticals, Aurobindo Pharma Limited and Ranbaxy Research Laboratories. He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali, India, 2003 and Bachelor of Pharmacy from Osmania University, India, 2001. 5 Disclosure of Not Applicable Not Applicable relationship between Directors This is for your information and records. Thanking you, Yours faithfully, For NATCO Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer Page 2 of 2